Literature DB >> 32988956

Socioeconomic status and HRT prescribing: a study of practice-level data in England.

Sarah Hillman1, Saran Shantikumar2, Ali Ridha3, Dan Todkill4, Jeremy Dale1.   

Abstract

BACKGROUND: Concerns have been raised that women from deprived backgrounds are less likely to be receiving hormone replacement therapy (HRT) treatment and its benefits, although evidence in support of this is lacking. AIM: To investigate general practice HRT prescription trends and their association with markers of socioeconomic deprivation. DESIGN AND
SETTING: Cross-sectional study of primary care prescribing data in England in 2018.
METHOD: Practice-level prescribing rate was defined as the number of items of HRT prescribed per 1000 registered female patients aged ≥40 years. The association between Index of Multiple Deprivation (IMD) score and HRT prescribing rate was tested using multivariate Poisson regression, adjusting for practice proportions of obesity, smoking, hypertension, diabetes, coronary heart disease and cerebrovascular disease, and practice list size.
RESULTS: The overall prescribing rate of HRT was 29% lower in practices from the most deprived quintile compared with the most affluent (incidence rate ratio [IRR] = 0.71; 95% confidence interval [CI] = 0.68 to 0.73). After adjusting for all cardiovascular disease outcomes and risk factors, the prescribing rate in the most deprived quintile was still 18% lower than in the least deprived quintile (adjusted IRR = 0.82; 95% CI = 0.77 to 0.86). In more deprived practices, there was a significantly higher tendency to prescribe oral HRT than transdermal preparations (P<0.001).
CONCLUSION: This study highlights inequalities associated with HRT prescription. This may reflect a large unmet need in terms of menopause care in areas of deprivation. Further research is needed to identify the factors from patient and GP perspectives that may explain this. © British Journal of General Practice 2020.

Entities:  

Keywords:  cross-sectional studies; female; general practice; hormone replacement therapy; menopause; prescribing

Mesh:

Year:  2020        PMID: 32988956      PMCID: PMC7523922          DOI: 10.3399/bjgp20X713045

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  13 in total

1.  Prescribing at the Primary Care Group level: census data and prescribing indicators.

Authors:  D C Lloyd; G Scrivener
Journal:  J Clin Pharm Ther       Date:  2001-04       Impact factor: 2.512

2.  A factor analytic study of climacteric symptoms.

Authors:  J G Greene
Journal:  J Psychosom Res       Date:  1976       Impact factor: 3.006

3.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.

Authors:  Rhoda H Cobin; Neil F Goodman
Journal:  Endocr Pract       Date:  2017-07       Impact factor: 3.443

4.  Time trends and geographical variation in prescribing of antibiotics in England 1998-2017.

Authors:  Helen J Curtis; Alex J Walker; Kamal R Mahtani; Ben Goldacre
Journal:  J Antimicrob Chemother       Date:  2019-01-01       Impact factor: 5.790

5.  Opioid prescribing trends and geographical variation in England, 1998-2018: a retrospective database study.

Authors:  Helen J Curtis; Richard Croker; Alex J Walker; Georgia C Richards; Jane Quinlan; Ben Goldacre
Journal:  Lancet Psychiatry       Date:  2018-12-20       Impact factor: 27.083

6.  Socioeconomic status and benzodiazepine and Z-drug prescribing: a cross-sectional study of practice-level data in England.

Authors:  Stephanie Soyombo; Rhian Stanbrook; Harpal Aujla; David Capewell; Mary Shantikumar; Farah Kidy; Daniel Todkill; Saran Shantikumar
Journal:  Fam Pract       Date:  2020-03-25       Impact factor: 2.267

Review 7.  Evidence-based assessment of the impact of the WHI on women's health.

Authors:  H G Burger; A H MacLennan; K-E Huang; C Castelo-Branco
Journal:  Climacteric       Date:  2012-06       Impact factor: 3.005

Review 8.  Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications.

Authors:  Franck Mauvais-Jarvis; JoAnn E Manson; John C Stevenson; Vivian A Fonseca
Journal:  Endocr Rev       Date:  2017-06-01       Impact factor: 19.871

9.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

10.  Patterns of use of hormone replacement therapy in one million women in Britain, 1996-2000.

Authors: 
Journal:  BJOG       Date:  2002-12       Impact factor: 6.531

View more
  2 in total

1.  Mortality in COVID-19 among women on hormone replacement therapy: a retrospective cohort study.

Authors:  Hajira Dambha-Miller; William Hinton; Christopher R Wilcox; Mark Joy; Michael Feher; Simon de Lusignan
Journal:  Fam Pract       Date:  2022-05-17       Impact factor: 2.290

2.  Inhaled anti-asthma therapies following hormone therapy in women: a nationwide cohort study.

Authors:  Erik Soeren Halvard Hansen; Kristian Aasbjerg; Amalie Lykkemark Moeller; Amani Meaidi; Elisabeth Juul Gade; Christian Torp-Pedersen; Vibeke Backer
Journal:  ERJ Open Res       Date:  2022-03-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.